SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — Oct 22, 2019
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: Oct. 22, 2019 · CIK: 0001534120 · Accession: 0001628280-19-012461
AI Filing Summary & Sentiment
File numbers found in text: 333-233978
Show Raw Text
CORRESP 1 filename1.htm Document 540 Gaither Road, Suite 400 Rockville, MD 20850 October 22, 2019 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Gregory Dundas Re: Cerecor Inc. Registration Statement on Form S-3 Filed September 27, 2019, as amended on October 18, 2019 File No. 333-233978 Ladies and Gentlemen: Cerecor Inc., a Delaware corporation (the “Registrant”), hereby requests that the Securities and Exchange Commission take appropriate action to make the Registration Statement on Form S-3 (File No. 333-233978) effective as of 4:05 p.m. Eastern Time, Thursday, October 24, 2019, or as soon thereafter as practicable. Please advise our corporate counsel, Andrew J. Gibbons at (919) 781-4000, of any questions. The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement. Very truly yours, CERECOR INC. By: /s/ Joseph M. Miller Name: Joseph M. Miller Title: Chief Financial Officer